1
Inhaled Ciclesonide for Outpatients With COVID19
Condition(s):COVID 19Last Updated:April 29, 2022Terminated
Ciclesonide: 86 Clinical Trials, Page 1 of 9
Hide Studies Not Open or Pending
2
A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19
Condition(s):COVID-19Last Updated:June 24, 2021Completed
3
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
Condition(s):Covid-19; Pneumonia, Viral; Sars-CoV2Last Updated:February 2, 2022Active, not recruiting
4
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
Condition(s):Seasonal Allergic RhinitisLast Updated:February 2, 2017Completed
5
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
Condition(s):Perennial Allergic RhinitisLast Updated:July 24, 2014Completed
6
The Mannitol-Asthma-Ciclesonide-Study
Condition(s):Asthma, BronchialLast Updated:July 25, 2019Completed
7
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
Condition(s):COVID-19Last Updated:January 11, 2022Completed
8
A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler
Condition(s):Allergic Rhinitis (AR)Last Updated:September 10, 2012Completed
9
Ciclesonide for the Treatment of Airway Hyperresponsiveness
Condition(s):AsthmaLast Updated:December 2, 2016Completed
10
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
Condition(s):Allergic RhinitisLast Updated:March 14, 2022Completed